Standardization and Validation of Cell-Based Assays for the Detection of Neutralizing Anti-Drug Antibodies

Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations

Volumn , Issue , 2011, Pages 243-268

  Finco Kent, Deborah ^a   Grenham, Amy ^a  

^a PFIZER INC   (United States)

Author keywords

Cell based assay, therapeutic protein function driving design of cell based NAb assay; Cell based assays, standardization and validation neutralizing anti drug antibody detection; Optimization of cell based assay, antibody detection assay performance for validation

Indexed keywords

EID: 84871437483     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075685.ch14     Document Type: Chapter

References (38)

1. Schellekens, H. ( 2002 ). Bioequivalence and the immunogenicity of biopharmaceuticals . Nature Rev Drug Discov, 1, 457-462 .
2. Li, J., Yang, C., Xia, Y., et al. ( 2001 ). Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood, 98, 3241-3248 .
3. Casadevall, N., Nataf, J., Viron, B., et al. ( 2002 ). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin . N Engl J Med, 346, 469-475 .
4. Cohen, B.A., Oger, J., Gagnon, A., et al. ( 2008 ). The implications of immunogenicity for protein-based multiple sclerosis therapies . J Neurol Sci, 275, 7-17 .
5. Ponce, R., Abad, L., Amaravadi, L., et al. ( 2009 ). Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies . Regul Toxicol Pharmacol, 54, 164-182 .
6. Shankar, G., Pendley, C., Stein, K.E., et al. ( 2007 ). A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs . Nature Biotechnol, 25, 555-561 .
7. Koren, E., Smith, H.W., Shoers, E., et al. ( 2008 ). Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products . J Immunol Methods, 333, 1-9 .
8. Schneider, C.K., Papaluca, M., Kurki, P. ( 2009 ). A European perspective on immunogenicity evaluation . Nature Biotechnol, 27, 507-508 .
9. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use . (2009). Addendum to ICH S6. Preclinical safety evaluation of biotechnology-derived pharmaceuticals, October 2009 .
10. European Medicines Agency (EMA) . ( 2007 ). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins . EMA/CHMP/BMWP/ 14327/2006.
11. Gupta, S ., Indelicato, S.R., Jethwa, V., et al. ( 2007 ). Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics . J Immunol Methods, 321, 1-18 .
12. European Medicines Agency (EMA) . (2010 ). Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use . EMA/CHMP/BMWP/ 86289/2010.
13. Deisenhammer, F., Schellekens, H., Bertolotto, A. ( 2004 ). Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis . J Neurol, 251 ( Suppl. 2 ), 31-39 .
14. Wang, J., Lozier, J., Johnson, G., et al. ( 2008 ). Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment . Nature Biotechnol, 26, 901-908 .
15. Mire-Sluis, A.R. ( 2001 ). Progress in the use of biological assays during the development of biotechnology products . Pharm Res, 9, 1239-1246 .
16. Brasier, A.R., Ron, D. ( 1992 ). Luciferase reporter gene assay in mammalian cells . Methods Enzymol, 216, 386-397 .
17. Hammer, M.M., Wehrman, T.S., Blau, H.M. ( 2007 ). A novel enzyme complementationbased assay for monitoring G-protein-coupled receptor internalization . FASEB, 21, 3827-3834 .
18. von Degenfeld, G., Wehrman, T.S., Hammer, M.M., Blau, H.M. . ( 2007 ). A universal technology for monitoring G-protein-coupled receptor activation in vitro and non-invasively in live animals . FASEB J, 21, 3819-3826 .
19. Whritenour, J., O ' Donnell, L., Donovan, C., Finco, D. ( 2009 ). Validation of a bioassay for the detection of neutralizing antibodies against a biotherapeutic peptide. Poster M1044. National AAPS meeting, Seattle, WA .
20. Meager, A. ( 2006 ). Measurement of cytokines by bioassays: theory and application . Methods, 38, 237-252 .
21. Lallemand, C., Meritet, J.F., Erickson, R., et al. ( 2008 ). Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene . J Interferon Cytokine Res, 28, 393-404 .
22. Gilli, F., van Beers, M., Marnetto, F., et al. ( 2008 ). Development of a bioassay for quantification of neutralizing antibodies against human interferon-beta in mouse sera . J Immunol Methods, 336, 119-126 .
23. Bertolotto, A., Sala, A., Caldanon, M., et al. ( 2007 ). Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta . J Immunol Methods, 321, 19-31 .
24. Wei, X., Swanson, S.J., Gupta, S. ( 2004 ). Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies . J Immunol Methods, 293, 115-126 .
25. Baltrukonis, D., Finco-Kent, D., Poirier, M., et al. ( 2006 ). Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870893 . J Immunotoxicol, 3, 157-164 .
26. Lam, R., Farrell, R., Aziz, T., et al. ( 2008 ). Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN ß in multiple sclerosis patients . J Immunol Methods, 336, 113-118 .
27. Hu, J., Gupta, S., Swanson, S.J., et al. ( 2009 ). A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum . J Immunol Methods, 345, 70-79 .
28. Pennucci, J.U., Swanson, S., Kaliyaperumal, A., Gupta, S. ( 2010 ). Multiplex evaluation of a cell-based assay for the detection of antidrug neutralizing antibodies to panitumumab in human serum using automated fluorescent microscopy . J Biomol Screen, 15 ( 6 ), 644-652 .
29. McCutcheon, K., Quarmby, V., Song, A. ( 2010 ). Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference . J Immunol Methods, 358, 35-45 .
30. Sadick, M.D., Intintoli, A., Quarmby, V., et al. ( 1999 ). Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays . J Pharm Biomed Anal, 19, 883-891 .
31. Perini, P., Calabrese, M., Biasi, G., Gallo, P. ( 2004 ). The clinical impact of interferon beta antibodies in relapsing-remitting MS . J Neurol, 251, 305-309 .
32. Polman, C., Kappos, L., White, R., et al. ( 2003 ). Neutralizing antibodies during treatment of secondary progressive MS with interferon ß-1b . Neurology, 60, 37-43 .
33. European Medicines Agency (EMA) . ( 2008 ). Beta-interferons and neutralizing antibodies (in multiple sclerosis) . EMA/CHMP/BWP/580136/2007.
34. Mire-Sluis, A.R., Barret, Y.C., Devanarayan, V., et al. ( 2004 ). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products . J Immunol Methods, 289, 1-16 .
35. Lofgren, J.A., Wala, I., Koren, E., et al. ( 2006 ). Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein . J Immunol Methods, 308, 101-108 .
36. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use . ( 2005 ). Q2(R1) . Validation of analytical procedures: text and methodology.
37. Shankar, G., Devanarayan, V., Amaravadi, L., et al. ( 2008 ). Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products . J Pharm Biomed Anal, 48, 1267-81 .
38. Chamberlain, P. ( 2008 ). Presenting an immunogenicity risk assessment to regulatory agencies . In Immunogenicity of Biopharmaceuticals . van de Weert M, Moller EH, eds. Springer, New York, 239-258 .